Ratain MJ - Search Results

1

Paradoxical relationship between acetylator phenotype and amonafide toxicity.

Ratain MJ, Mick R, Berezin F, Janisch L, Schilsky RL, Williams SF, Smiddy J. Ratain MJ, et al. Clin Pharmacol Ther. 1991 Nov;50(5 Pt 1):573-9. doi: 10.1038/clpt.1991.183. Clin Pharmacol Ther. 1991. PMID: 1934870

2

Limited sampling models for amonafide (NSC 308847) pharmacokinetics.

Ratain MJ, Staubus AE, Schilsky RL, Malspeis L. Ratain MJ, et al. Cancer Res. 1988 Jul 15;48(14):4127-30. Cancer Res. 1988. PMID: 3383202

3

Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study.

Ratain MJ, Rosner G, Allen SL, Costanza M, Van Echo DA, Henderson IC, Schilsky RL. Ratain MJ, et al. J Clin Oncol. 1995 Mar;13(3):741-7. doi: 10.1200/JCO.1995.13.3.741. J Clin Oncol. 1995. PMID: 7884434 Clinical Trial.

4

Bootstrap validation of pharmacodynamic models defined via stepwise linear regression.

Mick R, Ratain MJ. Mick R, et al. Among authors: ratain mj. Clin Pharmacol Ther. 1994 Aug;56(2):217-22. doi: 10.1038/clpt.1994.126. Clin Pharmacol Ther. 1994. PMID: 8062499 Clinical Trial.

5

Modulation of vinblastine resistance with cyclosporine: a phase I study.

Samuels BL, Mick R, Vogelzang NJ, Williams SF, Schilsky RL, Safa AR, O'Brien SM, Ratain MJ. Samuels BL, et al. Among authors: ratain mj. Clin Pharmacol Ther. 1993 Oct;54(4):421-9. doi: 10.1038/clpt.1993.169. Clin Pharmacol Ther. 1993. PMID: 8222485 Clinical Trial.

6

Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456).

Vogelzang NJ, Mick R, Janisch L, Berezin F, Schilsky RL, Ratain MJ. Vogelzang NJ, et al. Among authors: ratain mj. Cancer Res. 1994 Jan 1;54(1):114-9. Cancer Res. 1994. PMID: 8261430 Clinical Trial.

7

Phase I study of amonafide dosing based on acetylator phenotype.

Ratain MJ, Mick R, Berezin F, Janisch L, Schilsky RL, Vogelzang NJ, Lane LB. Ratain MJ, et al. Cancer Res. 1993 May 15;53(10 Suppl):2304-8. Cancer Res. 1993. PMID: 8485716 Clinical Trial.

8

Etoposide combined with interferon alfa-2b: novel exploitation of established etoposide pharmacokinetics and pharmacodynamics.

Mick R, Vokes EE, Lestingi TM, Gray-Stern W, Fleming GF, Schilsky RL, Ratain MJ. Mick R, et al. Among authors: ratain mj. Clin Pharmacol Ther. 1996 Mar;59(3):349-59. doi: 10.1016/S0009-9236(96)80013-0. Clin Pharmacol Ther. 1996. PMID: 8653998 Clinical Trial.

9

Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender.

Ratain MJ, Mick R, Janisch L, Berezin F, Schilsky RL, Vogelzang NJ, Kut M. Ratain MJ, et al. Pharmacogenetics. 1996 Feb;6(1):93-101. doi: 10.1097/00008571-199602000-00008. Pharmacogenetics. 1996. PMID: 8845865

10

Pharmacodynamics in cancer therapy.

Ratain MJ, Schilsky RL, Conley BA, Egorin MJ. Ratain MJ, et al. J Clin Oncol. 1990 Oct;8(10):1739-53. doi: 10.1200/JCO.1990.8.10.1739. J Clin Oncol. 1990. PMID: 2213109 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

574 results

Search Page

Filters